ES2651692T3 - Anticuerpos anti-TLR4 y sus usos - Google Patents

Anticuerpos anti-TLR4 y sus usos Download PDF

Info

Publication number
ES2651692T3
ES2651692T3 ES13715871.3T ES13715871T ES2651692T3 ES 2651692 T3 ES2651692 T3 ES 2651692T3 ES 13715871 T ES13715871 T ES 13715871T ES 2651692 T3 ES2651692 T3 ES 2651692T3
Authority
ES
Spain
Prior art keywords
seq
amino acid
acid sequence
antibody
tlr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13715871.3T
Other languages
English (en)
Spanish (es)
Inventor
Francois Rousseau
Jérémy LOYAU
Nicolas Fischer
Greg Elson
Marie Kosco-Vilbois
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novimmune SA
Original Assignee
Novimmune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune SA filed Critical Novimmune SA
Application granted granted Critical
Publication of ES2651692T3 publication Critical patent/ES2651692T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES13715871.3T 2012-03-29 2013-03-29 Anticuerpos anti-TLR4 y sus usos Active ES2651692T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261617164P 2012-03-29 2012-03-29
US201261617164P 2012-03-29
PCT/US2013/034543 WO2013149111A2 (fr) 2012-03-29 2013-03-29 Anticorps anti-tlr4 et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
ES2651692T3 true ES2651692T3 (es) 2018-01-29

Family

ID=48087767

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13715871.3T Active ES2651692T3 (es) 2012-03-29 2013-03-29 Anticuerpos anti-TLR4 y sus usos

Country Status (11)

Country Link
US (4) US9453076B2 (fr)
EP (1) EP2831117B1 (fr)
JP (2) JP6419064B2 (fr)
CN (2) CN107868128A (fr)
AU (1) AU2013237929B2 (fr)
CA (1) CA2869048C (fr)
DK (1) DK2831117T3 (fr)
ES (1) ES2651692T3 (fr)
HU (1) HUE037613T2 (fr)
PL (1) PL2831117T3 (fr)
WO (1) WO2013149111A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2173381B1 (fr) * 2007-05-14 2013-10-02 NovImmune SA Polypeptides de liaison aux récepteurs fc à fonctions effectrices modifiées
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (fr) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l antigène capable de se lier à deux molécules d antigène ou plus de manière répétée
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
CA2869048C (fr) 2012-03-29 2023-10-17 Novimmune S.A. Anticorps anti-tlr4 et utilisations de ceux-ci
CA2932787A1 (fr) 2013-12-06 2015-06-11 Novimmune S.A. Anticorps anti-tlr4 et leurs methodes d'utilisation
CA2941014A1 (fr) 2014-02-28 2015-09-03 Astellas Pharma Inc. Nouvel anticorps bispecifique se liant au tlr2 humain et au tlr4 humain
CN104013979B (zh) * 2014-05-28 2016-06-15 上海纳米技术及应用国家工程研究中心有限公司 肠道靶向造影剂的制备方法
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201710322VA (en) * 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
WO2016125495A1 (fr) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Anticorps comprenant un domaine se liant à l'antigène dépendant de la concentration d'ions, variants de la région fc, anticorps se liant à l'il-8, et leurs utilisations
CN105949319A (zh) * 2016-04-27 2016-09-21 柳州市工人医院 作为TLR4信号通路抑制剂用于结肠癌治疗的sTLR4和MD2蛋白复合物
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
US20210393711A1 (en) 2018-10-11 2021-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Bacteria expressing single chain antibodies against toll-like receptors
CN115697410A (zh) * 2020-04-20 2023-02-03 艾德沙生物科技研究公司 用于治疗急性呼吸窘迫综合征的组合物和方法
GB202408008D0 (en) * 2024-06-05 2024-07-17 Cambridge Entpr Ltd TLR4 antibody

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0479909B1 (fr) 1989-06-29 1996-10-30 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (fr) 1991-05-14 1992-11-26 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
AU681997B2 (en) 1991-09-05 1997-09-18 University Of Connecticut, The Targeted delivery of poly- or oligonucleotides to cells
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
EP0745134A1 (fr) 1994-02-22 1996-12-04 Danafarber Cancer Institute Systeme de liberation d'acide nucleique, son procede de synthese et ses utilisations
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
WO1996034096A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
DK1711531T3 (da) * 2003-12-10 2012-04-30 Novimmune Sa Neutraliserende anti-TLR4/-MD-2-antistoffer og fremgangsmåder til anvendelse deraf
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
DE602005021694D1 (de) * 2004-12-10 2010-07-15 Novimmune Sa Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
EP2173381B1 (fr) * 2007-05-14 2013-10-02 NovImmune SA Polypeptides de liaison aux récepteurs fc à fonctions effectrices modifiées
WO2009138494A2 (fr) 2008-05-15 2009-11-19 Ablynx N.V. Séquences d'acides aminés dirigées contre des récepteurs du type toll et polypeptides comprenant celles-ci pour le traitement de maladies apparentées aux récepteurs du type toll
MX2011004674A (es) * 2008-11-04 2011-05-25 Idera Pharmaceuticals Inc Modulacion de la expresion del receptor 4 tipo larga distancia por oligonucleotidos antisentido.
KR101653030B1 (ko) * 2010-08-13 2016-08-31 로슈 글리카트 아게 항-테나신-c a２ 항체 및 이의 사용 방법
WO2012096917A1 (fr) * 2011-01-10 2012-07-19 Novimmune S.A. Anticorps anti-tlr4 et leurs procédés d'utilisation
CA2869048C (fr) 2012-03-29 2023-10-17 Novimmune S.A. Anticorps anti-tlr4 et utilisations de ceux-ci
CN105899231A (zh) * 2013-10-22 2016-08-24 诺夫免疫股份有限公司 用于在具有升高水平的tlr4配体和其它生物标记的患者中诊断和治疗病症的方法和组合物
CA2932787A1 (fr) * 2013-12-06 2015-06-11 Novimmune S.A. Anticorps anti-tlr4 et leurs methodes d'utilisation

Also Published As

Publication number Publication date
US20170008967A1 (en) 2017-01-12
EP2831117A2 (fr) 2015-02-04
CN104540851B (zh) 2017-09-15
DK2831117T3 (en) 2017-12-18
CN107868128A (zh) 2018-04-03
AU2013237929B2 (en) 2017-09-14
JP2019038816A (ja) 2019-03-14
AU2013237929A1 (en) 2014-11-06
JP6419064B2 (ja) 2018-11-07
HUE037613T2 (hu) 2018-09-28
CN104540851A (zh) 2015-04-22
WO2013149111A2 (fr) 2013-10-03
PL2831117T3 (pl) 2018-03-30
US10982004B2 (en) 2021-04-20
US20200207866A1 (en) 2020-07-02
EP2831117B1 (fr) 2017-11-01
JP2015514094A (ja) 2015-05-18
CA2869048C (fr) 2023-10-17
US20220324994A1 (en) 2022-10-13
US20130315914A1 (en) 2013-11-28
CA2869048A1 (fr) 2013-10-03
US9453076B2 (en) 2016-09-27
US10400044B2 (en) 2019-09-03
WO2013149111A3 (fr) 2014-01-30

Similar Documents

Publication Publication Date Title
US10982004B2 (en) Anti-TLR4 antibodies and uses thereof
ES2441189T3 (es) Polipéptidos de unión al receptor de Fc con funciones efectoras modificadas
ES2784631T3 (es) Anticuerpos anti-CD47 y métodos de uso de los mismos
US11260117B2 (en) Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
ES2727487T3 (es) Anticuerpos neutralizantes y métodos de uso de los mismos
US12448444B2 (en) Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof
US20180142018A1 (en) Anti-cd19 antibodies and methods of use thereof
CA3212599A1 (fr) Anticorps bispecifiques ciblant cd47 et pd-l1 et leurs methodes d'utilisation